| Not Yet Recruiting | Intratumoral N17350 in Advanced Solid Tumors NCT07339176 | Onchilles Pharma Inc | Phase 1 / Phase 2 |
| Recruiting | Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC NCT06912087 | University of Chicago | Phase 1 |
| Recruiting | Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial NCT06669572 | University of Chicago | Phase 2 |
| Completed | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V9 NCT06295809 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Recruiting | Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma NCT06383728 | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Completed | Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa NCT06094829 | Hospices Civils de Lyon | — |
| Recruiting | Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial NCT05955924 | Women's College Hospital | Phase 3 |
| Unknown | A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma. NCT02743832 | Jinsong Hou | N/A |
| Recruiting | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patient NCT05252078 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Unknown | Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carci NCT05845632 | Maastricht University Medical Center | — |
| Recruiting | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associ NCT04564989 | UNC Lineberger Comprehensive Cancer Center | — |
| Recruiting | TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY NCT04481256 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Recruiting | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven NCT04429542 | Bicara Therapeutics | Phase 1 |
| Recruiting | Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma NCT04099290 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | GDF15 Based TPF Induction Chemotherapy for OSCC Patients NCT02285530 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Terminated | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhi NCT03906526 | Celgene | Phase 1 |
| Completed | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced C NCT03833167 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Unknown | Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial NCT03769285 | Women's College Hospital | Phase 2 |
| Recruiting | Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC NCT03370406 | Melissa Pugliano-Mauro | Phase 1 |
| Active Not Recruiting | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma NCT03336606 | Providence Health & Services | Phase 1 |
| Active Not Recruiting | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Car NCT03174275 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Terminated | EPR Tumor Oximetry With CE India Ink NCT03321903 | Philip Schaner | — |
| Active Not Recruiting | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers NCT02994069 | Susanne Arnold | Phase 2 |
| Completed | Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin NCT02883556 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer NCT03067610 | University of Texas Southwestern Medical Center | Phase 2 |
| Unknown | The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma NCT02916368 | Beijing Tongren Hospital | — |
| Terminated | A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients NCT02285543 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Completed | P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC NCT03077243 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage NCT02290145 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Completed | Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity NCT02442375 | Radboud University Medical Center | Phase 3 |
| Unknown | Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers NCT02666833 | Massachusetts General Hospital | — |
| Unknown | Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients NCT02526953 | Blokhin's Russian Cancer Research Center | Phase 3 |
| Terminated | Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatm NCT02438995 | Northwell Health | Phase 1 |
| Active Not Recruiting | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer NCT02664935 | University of Birmingham | Phase 2 |
| Terminated | Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma NCT02549638 | Mayo Clinic | — |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Ep NCT02269020 | Centre Hospitalier Universitaire de Nīmes | Phase 1 |
| Unknown | Olaparib and Radiotherapy in Head and Neck Cancer NCT02229656 | The Netherlands Cancer Institute | Phase 1 |
| Completed | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Car NCT02218164 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study NCT02281955 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer NCT02107235 | Traws Pharma, Inc. | Phase 1 |
| Terminated | Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma NCT02045186 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Unknown | STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE NCT02328391 | Grupo Gallego de Cancer de Pulmon | — |
| Completed | Spanish Registry of Mohs Surgery NCT02310503 | Fundación Academia Española de Dermatología | — |
| Completed | Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis NCT01728233 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer NCT01494415 | First People's Hospital of Hangzhou | Phase 2 |
| Completed | De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous NCT01530997 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent a NCT01345682 | Boehringer Ingelheim | Phase 3 |
| Unknown | Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols NCT01496521 | Beijing Friendship Hospital | Phase 3 |
| Terminated | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer NCT01441128 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma NCT01195922 | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 1 / Phase 2 |
| Unknown | Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) NCT01129154 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Withdrawn | Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract NCT01175499 | University of California, San Francisco | N/A |
| Completed | Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers NCT01104714 | Centre Hospitalier Universitaire de Nīmes | — |
| Terminated | An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Che NCT01142869 | Merck KGaA, Darmstadt, Germany | — |
| Completed | CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial NCT00847912 | VA Office of Research and Development | Phase 4 |
| Completed | Detecting Lesions in the Oral Cavity With Thermal Imaging NCT00868725 | Sheba Medical Center | — |
| Terminated | Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk NCT00937612 | Chang Gung Memorial Hospital | N/A |
| Completed | Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomograph NCT00671437 | Washington University School of Medicine | Phase 2 |
| Terminated | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer NCT00673049 | Pfizer | Phase 3 |
| Terminated | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, L NCT00596830 | Pfizer | Phase 3 |
| Terminated | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung NCT00632203 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer NCT00660218 | State University of New York - Upstate Medical University | Phase 1 / Phase 2 |
| Unknown | Phase II AK Study in Organ Transplant Patients NCT00829192 | Clinuvel Pharmaceuticals Limited | Phase 2 |
| Completed | Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin NCT00875381 | Mayo Clinic | — |
| Completed | Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck NCT00534950 | King Faisal Specialist Hospital & Research Center | N/A |
| Completed | BIBW 2992 (Afatinib) in Head & Neck Cancer NCT00514943 | Boehringer Ingelheim | Phase 2 |
| Completed | Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of NCT00474825 | National Baromedical Services | Phase 1 |
| Terminated | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemothe NCT00490061 | Quynh-Thu Le | Phase 2 |
| Withdrawn | Acitretin Plasma Levels Under Hemodialysis NCT00488384 | Günther Hofbauer | Phase 4 |
| Terminated | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and N NCT00448240 | Henry Ford Health System | Phase 2 / Phase 3 |
| Completed | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia NCT01362127 | Karolinska University Hospital | Phase 2 |
| Completed | A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck NCT00358930 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 |
| Terminated | Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer NCT00368329 | Stanford University | Phase 1 |
| Completed | Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma I NCT00329121 | Peplin | Phase 2 |
| Terminated | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer NCT00272181 | Sesen Bio, Inc. | Phase 2 |
| Terminated | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and N NCT00412776 | Sesen Bio, Inc. | Phase 2 / Phase 3 |
| Completed | Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR NCT00240682 | Centre Hospitalier of Chartres | Phase 2 |
| Unknown | A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Bra NCT00122239 | AHS Cancer Control Alberta | — |
| Completed | Simultaneous Integrated Boost (SIB)- IMRT NCT00389727 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Terminated | Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Ne NCT02254044 | Boehringer Ingelheim | Phase 1 |
| Terminated | Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) NCT00073450 | Merck Sharp & Dohme LLC | Phase 2 |
| Withdrawn | Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Hea NCT00233636 | AstraZeneca | Phase 2 |
| Completed | Post-Operative Drainage Following Lymph Node Dissection NCT00324272 | Oxford University Hospitals NHS Trust | Phase 4 |
| Completed | TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN NCT00539630 | Sanofi | Phase 3 |
| Completed | Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation NCT00313027 | Stanford University | N/A |
| Completed | Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck NCT00185835 | Stanford University | Phase 1 |
| Completed | Docetaxel in Non Small Cell Lung Cancer (NSCLC) NCT00432315 | Sanofi | Phase 2 |
| Terminated | Patient Evaluation for Head and Neck Surgery Branch Studies NCT00011492 | National Institute on Deafness and Other Communication Disorders (NIDCD) | — |
| Terminated | A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma NCT00190554 | Japan Clinical Oncology Group | Phase 3 |
| Terminated | Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcino NCT00563862 | Hospital Authority, Hong Kong | N/A |
| Completed | A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer NCT00038584 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) NCT00563927 | Hospital Authority, Hong Kong | N/A |
| Completed | Hardwins - Squamous Cell Carcinoma Head & Neck (Surgery/RT) NCT00188318 | University Health Network, Toronto | Phase 2 |
| Completed | Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer NCT00007631 | US Department of Veterans Affairs | Phase 3 |
| Unknown | Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Meth NCT00041613 | Introgen Therapeutics | Phase 3 |
| Withdrawn | Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Ne NCT01491139 | University College, London | Phase 1 |
| Unknown | Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone NCT00041626 | Introgen Therapeutics | Phase 3 |